Damon Runyon Researchers

Dr. Lee [HHMI Fellow] studies how the cells and molecules of the immune system within the tumor microenvironment contribute to initiation, tumor progression, and responses to anti-cancer therapy. Of the immune components, cells called interleukin-17-secreting lymphocytes have pivotal pathogenic roles in multiple cancers. He aims to elucidate the regulatory mechanisms by which this pathogenicity is controlled. Ultimately, a better understanding of the pathways may suggest promising targets for therapeutic strategies aimed at reducing the risk of cancer.